Please use this identifier to cite or link to this item: http://repository.icesi.edu.co/biblioteca_digital/handle/10906/81246
Full metadata record
DC FieldValueLanguage
dc.creatorValero, Antoniospa
dc.creatorSánchez López, Jaimespa
dc.creatorBartra, Joanspa
dc.creatorSerrano Reyes, Carlos Danielspa
dc.creatorMuñoz-Cano, Rosaspa
dc.creatorRoca, Jordispa
dc.creatorPicado, Cesarspa
dc.date.accessioned2017-03-30T22:42:05Z-
dc.date.available2017-03-30T22:42:05Z-
dc.date.issued2011-09-01-
dc.identifier.issn1423-0097-
dc.identifier.otherhttp://www.ncbi.nlm.nih.gov/pubmed/21597303spa
dc.identifier.otherhttp://www.karger.com/doi/10.1159/000322841spa
dc.identifier.urihttp://hdl.handle.net/10906/81246-
dc.descriptionBACKGROUND Aspirin-exacerbated respiratory disease (AERD) affects a subset of patients with asthma. Cyclooxygenase 2 inhibitors are a safe alternative in patients with AERD. Parecoxib is the first cyclooxygenase 2 selective drug for parenteral administration, especially useful after surgery thanks to its analgesic power. The aim of the study is to assess the tolerance of parecoxib (Dynastat; Pfizer) given by intramuscular route in patients with AERD. METHODS Patients evaluated were referred to the Pneumology and Respiratory Allergy Department of the Hospital Clinic (Barcelona, Spain) for asthma exacerbations precipitated by 2 or more different non-steroidal anti-inflammatory drugs (NSAIDs). AERD was confirmed by a nasal challenge test with aspirin. Patients were challenged with parecoxib, and urine samples were collected to measure the leukotriene E(4) concentration. RESULTS Ten patients were challenged with parecoxib. No symptoms were reported with any of the administered doses, and there were no signs of immediate or delayed hypersensitivity. There were no alterations in the forced expiratory volume in 1 s or in acoustic rhinometry measurements. No significant differences between leukotriene E(4) levels were detected. CONCLUSION The drug was well tolerated by all patients, with no adverse reactions. This lack of reactions found in our study supports the fact that parecoxib could be a safe alternative in postsurgery analgesia in NSAID-intolerant asthma patients.eng
dc.format.extent221–223 páginas-
dc.format.extentDigitalspa
dc.language.isoengeng
dc.relation.ispartofInternational Archives of Allergy and Immunology - Vol. 156, No. 2 - 2011spa
dc.rightsEL AUTOR, expresa que la obra objeto de la presente autorización es original y la elaboró sin quebrantar ni suplantar los derechos de autor de terceros, y de tal forma, la obra es de su exclusiva autoría y tiene la titularidad sobre éste. PARÁGRAFO: en caso de queja o acción por parte de un tercero referente a los derechos de autor sobre el artículo, folleto o libro en cuestión, EL AUTOR, asumirá la responsabilidad total, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos, la Universidad Icesi actúa como un tercero de buena fe. Esta autorización, permite a la Universidad Icesi, de forma indefinida, para que en los términos establecidos en la Ley 23 de 1982, la Ley 44 de 1993, leyes y jurisprudencia vigente al respecto, haga publicación de este con fines educativos. Toda persona que consulte ya sea la biblioteca o en medio electrónico podrá copiar apartes del texto citando siempre la fuentes, es decir el título del trabajo y el autor.spa
dc.subjectEnfermedades respiratoriasspa
dc.subjectAlergia Respiratoria-
dc.subjectAsma - Tratamientospa
dc.subjectCiencias socio biomédicasspa
dc.subjectMedical scienceseng
dc.titleSafety of Parecoxib in Asthmatic Patients with Aspirin-Exacerbated Respiratory Diseasespa
dc.typeinfo:eu-repo/semantics/article-
dc.audienceComunidad Universidad Icesi – Investigadores-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.type.spaArtículo-
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion-
dc.citation.volume156spa
dc.citation.issue2-
dc.identifier.doihttp://dx.doi.org/10.1159/000322841-
Appears in Collections:Nuevo conocimiento - BIO
Nuevo conocimiento - FVL

Files in This Item:
File SizeFormat 
documento.html274 BHTMLView/Open




This item is licensed under a Creative Commons License Creative Commons